A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
Tuli, Richard, Shiao, Stephen L, Nissen, Nicholas, Tighiouart, Mourad, Kim, Sungjin, Osipov, Arsen, Bryant, Miranda, Ristow, Lindsey, Placencio-Hickok, Veronica, Hoffman, David, Rokhsar, Sepehr, Scher, Kevin, Klempner, Samuel J, Noe, Paul, Davis, M.J., Wachsman, Ashley, Lo, Simon, Jamil, Laith, Sandler, Howard, Piantadosi, Steven, Hendifar, Andrew
Published in EBioMedicine (01.02.2019)
Published in EBioMedicine (01.02.2019)
Get full text
Journal Article
Abstract OT2-04-04: Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase 2 trial
McArthur, Heather, Leal, Jorge, Page, David, Abaya, Christina DiLauro, Basho, Reva, Ristow, Lindsey, Coleman, Hannah, Shiao, Stephen, Knott, Simon, Mita, Monica, Tighiouart, Mourad, Chung, Alice, Dadmanesh, Farnaz, McAndrew, Philomena, Karlan, Scott, Verma, Sunil, Giuliano, Armando
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article